Resection techniques for recurrent glioblastoma
Official title: The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2301)
Run by Erasmus Medical Center · NCT06273176 · Data updated 2026-11-12
This study is testing different methods of mapping the brain during surgery for recurring glioblastoma to see which one helps patients keep their movement and speech abilities while removing as much of the tumor as possible.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 90 Years |
| Sex | All |
| Enrollment | 225 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 8 sites (San Francisco, California and 7 other locations) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | February 22, 2024 |
| Trial ID | NCT06273176 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 90 with recurrent glioblastoma tumors located in or near eloquent brain areas.
✕Probably not a fit
Patients with tumors in the cerebellum, brainstem, or midline, or those with multifocal lesions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares the effects of awake mapping, asleep mapping, and no mapping techniques during the resection of recurrent glioblastoma tumors. It is an international, multicenter, prospective cohort study that aims to evaluate the safety and effectiveness of these mapping methods in preserving motor and language functions while maximizing tumor resection. Patients with tumors located in or near eloquent brain areas will be included, and the study will assess the extent of tumor resection and patient outcomes. The study is part of the ENCRAM Research Consortium and involves several prominent neurosurgical centers.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and functional preservation for patients undergoing reoperation for recurrent glioblastoma.
How similar studies have gone: Similar studies have shown success with mapping techniques in newly diagnosed glioblastoma, but the effects in recurrent cases are less understood, making this approach somewhat novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years and ≤90 years 2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma 3. Tumors situated in or near eloquent areas; motor cortex, sensory cortex, subcortical pyramidal tract, speech areas or visual areas as indicated on MRI (Sawaya Grading II and II)19 4. The tumor is suitable for resection (according to neurosurgeon) 5. Written informed consent Exclusion Criteria: 1. Tumors of the cerebellum, brainstem, or midline 2. Multifocal contrast-enhancing lesions 3. Medical reasons precluding MRI (e.g., pacemaker) 4. Inability to give written informed consent 5. Secondary high-grade glioma due to malignant transformation from low-grade glioma 6. Clinical data unavailable for the newly diagnosed setting
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
University Hospital Leuven
Leuven, Belgium Recruiting -
Universitätsklinikum Heidelberg
Heidelberg, Germany Recruiting -
Erasmus Medical Center
Rotterdam, South Holland, Netherlands Recruiting -
Haaglanden Medical Center
The Hague, Netherlands Recruiting
Show 2 more locations
-
Technical University Munich
Munich, Germany Not yet recruiting -
Inselspital Universitätsspital Bern
Bern, Switzerland Not yet recruiting
Study contacts
- Principal investigator: Jasper Gerritsen, MD PhD — Erasmus Medical Center
- Study coordinator: Jasper Gerritsen, MD PhD
- Email: j.gerritsen@erasmusmc.nl
- Phone: +31107036130
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing surgery and best treatment for recurrent glioblastoma
This study is testing whether surgery or the best available treatment helps people with recurring glioblastoma feel better and live longer.
-
Comparing two surgical approaches for high-grade glioma patients
This study is testing whether a more extensive surgical method for removing high-grade brain tumors helps patients live longer and feel better compared to a standard approach.
-
Metabolic profiling of glioblastoma using advanced imaging techniques
This study is testing new imaging techniques to see how glioblastoma tumors use energy and nutrients, which could help doctors understand the tumors better and improve treatment options.
-
Comparing tumor resection and biopsy for high-grade glioma patients
This study is testing whether removing a brain tumor or just taking a small sample helps older patients with high-grade gliomas live longer and feel better afterward.
-
Comparing awake craniotomy and general anesthesia for glioblastoma surgery
This study is testing whether having brain surgery while awake is safer and more effective than having it under general anesthesia for people with glioblastoma in important areas of the brain.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.